▲ +106.06% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Biomerica in the last 3 months. The average price target is $11.33, with a high forecast of $13.00 and a low forecast of $10.00. The average price target represents a 106.06% upside from the last price of $5.50.
The current consensus among 3 contributing investment analysts is to buy stock in Biomerica. This Buy consensus rating has held steady for over two years.
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.